market-trends is the sole category represented across all 1 tracked stories. Compass Pathways plc is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 54 original sources each against 6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Compass Pathways plc
market-trends is the sole category represented across all 1 tracked stories. Compass Pathways plc is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. They are better corroborated than the beat average, carrying 54 original sources each against 6 for the same window. Their average consequence score of 7 runs above the beat's 5.8 for that window. We currently track 1 Healthcare story that mention Compass Pathways plc, all published on February 20, 2026.
Stories tracked
1
Sources per story
54
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Compass Pathways plc. Shared-story counts are live from our verified record — not editorial picks.
A wave of earnings reports and clinical trial results has triggered significant volatility across the healthcare and biotech sectors. While Genmab reported a decline in full-year profits, breakthrough Phase 3 results from Compass Pathways and Ocular Therapeutix highlight a sharp divergence between clinical success and market valuation.